DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mager, D. E.
Right arrow Articles by Jusko, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mager, D. E.
Right arrow Articles by Jusko, W. J.

Vol. 31, Issue 5, 510-518, May 2003

MINIREVIEW
Diversity of Mechanism-Based Pharmacodynamic Models

Donald E. Mager,1 Elzbieta Wyska,2 and William J. Jusko

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York

Pharmacodynamics is the study of the time course of pharmacological effects of drugs. The field of pharmacodynamic modeling has made many advances, due in part to the relatively recent development of basic and extended mechanism-based models. The purpose of this article is to describe the classic as well as contemporary approaches, with an emphasis on pertinent equations and salient model features. In addition, current methods of integrating various system complexities into these models are discussed. Future pharmacodynamic models will most likely reflect an assembly of the basic components outlined in this review.

1 Current address: Gerontology Research Center, 5600 Nathan Shock Dr., Baltimore, MD 21224.

2 Current address: Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University, 9 Medyczna St., 30-688 Krakow, Poland.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
H.-Y. Cho, R. A. Blum, T. Sunderland, G. J. S. Cooper, and W. J. Jusko
Pharmacokinetic and Pharmacodynamic Modeling of a Copper-Selective Chelator (TETA) in Healthy Adults
J. Clin. Pharmacol., August 1, 2009; 49(8): 916 - 928.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. K. Abraham, D. E. Mager, X. Gao, M. Li, D. R. Healy, and T. S. Maurer
Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 169 - 178.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Wong, M. Belvin, S. Herter, K. P. Hoeflich, L. J. Murray, L. Wong, and E. F. Choo
Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 360 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Yamazaki, J. Skaptason, D. Romero, J. H. Lee, H. Y. Zou, J. G. Christensen, J. R. Koup, B. J. Smith, and T. Koudriakova
Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models
Drug Metab. Dispos., July 1, 2008; 36(7): 1267 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Plock, C. Buerger, C. Joukhadar, S. Kljucar, and C. Kloft
Does Linezolid Inhibit Its Own Metabolism? Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients
Drug Metab. Dispos., October 1, 2007; 35(10): 1816 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Woo, W. Krzyzanski, and W. J. Jusko
Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in Rats
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1297 - 1306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. D. Arnold, D. E. Mager, J. E. Slack, and R. M. Straubinger
Effect of Repetitive Administration of Doxorubicin-Containing Liposomes on Plasma Pharmacokinetics and Drug Biodistribution in a Rat Brain Tumor Model
Clin. Cancer Res., December 15, 2005; 11(24): 8856 - 8865.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. E. Mager, D. R. Abernethy, J. M. Egan, and D. Elahi
Exendin-4 Pharmacodynamics: Insights from the Hyperglycemic Clamp Technique
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 830 - 835.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.